(Q46395433)

21 December 2017

title

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia (English)

1 reference

21 December 2017

0 references

1 reference

2

Mason W Freeman

1 reference

21 December 2017

author name string

Michel Farnier

1

1 reference

21 December 2017

Geraldine Macdonell

3

1 reference

21 December 2017

Inna Perevozskaya

4

1 reference

21 December 2017

Michael J Davies

5

1 reference

21 December 2017

Yale B Mitchel

6

1 reference

21 December 2017

Barry Gumbiner

7

1 reference

21 December 2017

Ezetimibe Study Group

8

1 reference

21 December 2017

publication date

21 March 2005

1 reference

21 December 2017

published in

European Heart Journal

1 reference

21 December 2017

volume

26

1 reference

21 December 2017

issue

9

1 reference

21 December 2017

page(s)

897-905

1 reference

21 December 2017

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI231

1 reference

The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI231

Effects of fibrates on serum metabolic parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI231

Statin-fibrate combination: therapy for hyperlipidemia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI231

Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI231

Statin-fibrate combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI231

Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI231

Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI231

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI231

Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI231

Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI231

Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI231

Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI231

Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI231

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI231

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI231

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI231

Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI231

Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI231

21 January 2018

Identifiers

DOI

10.1093/EURHEARTJ/EHI231

1 reference

21 December 2017

PubMed ID

15781429

1 reference

21 December 2017